Insights on the Use of ?-Lipoic Acid for Therapeutic Purposes

Basit Öğe Kaydı
dc.authoridLobine, Devina/0000-0002-6398-0371
dc.authoridSharifi-Rad, Javad/0000-0002-7301-8151
dc.authoridCruz-Martins, Natalia/0000-0002-5934-5201
dc.authoridSharopov, Farukh/0000-0003-0378-8887
dc.authoridCapanoglu, Esra/0000-0003-0335-9433
dc.authoridAkram, Muhammad/0000-0002-7457-8572
dc.contributor.authorSalehi, Bahare
dc.contributor.authorYilmaz, Yakup Berkay
dc.contributor.authorAntika, Gizem
dc.contributor.authorTumer, Tugba Boyunegmez
dc.contributor.authorMahomoodally, Mohamad Fawzi
dc.contributor.authorLobine, Devina
dc.contributor.authorAkram, Muhammad
dc.date.accessioned2025-01-27T20:49:42Z
dc.date.available2025-01-27T20:49:42Z
dc.date.issued2019
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractalpha-lipoic acid (ALA, thioctic acid) is an organosulfur component produced from plants, animals, and humans. It has various properties, among them great antioxidant potential and is widely used as a racemic drug for diabetic polyneuropathy-associated pain and paresthesia. Naturally, ALA is located in mitochondria, where it is used as a cofactor for pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase complexes. Despite its various potentials, ALA therapeutic efficacy is relatively low due to its pharmacokinetic profile. Data suggests that ALA has a short half-life and bioavailability (about 30%) triggered by its hepatic degradation, reduced solubility as well as instability in the stomach. However, the use of various innovative formulations has greatly improved ALA bioavailability. The R enantiomer of ALA shows better pharmacokinetic parameters, including increased bioavailability as compared to its S enantiomer. Indeed, the use of amphiphilic matrices has capability to improve ALA bioavailability and intestinal absorption. Also, ALA's liquid formulations are associated with greater plasma concentration and bioavailability as compared to its solidified dosage form. Thus, improved formulations can increase both ALA absorption and bioavailability, leading to a raise in therapeutic efficacy. Interestingly, ALA bioavailability will be dependent on age, while no difference has been found for gender. The present review aims to provide an updated on studies from preclinical to clinical trials assessing ALA's usages in diabetic patients with neuropathy, obesity, central nervous system-related diseases and abnormalities in pregnancy.
dc.description.sponsorshipPortuguese Foundation for Science and Technology (FCT-Portugal) [UID/BIM/04293/2013]; NORTE2020 - Northern Regional Operational Program [NORTE-01-0145-FEDER-000012]
dc.description.sponsorshipN. Martins would like to thank the Portuguese Foundation for Science and Technology (FCT-Portugal) for the Strategic project ref. UID/BIM/04293/2013 and NORTE2020 - Northern Regional Operational Program (NORTE-01-0145-FEDER-000012).
dc.identifier.doi10.3390/biom9080356
dc.identifier.issn2218-273X
dc.identifier.issue8
dc.identifier.pmid31405030
dc.identifier.scopus2-s2.0-85071386907
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3390/biom9080356
dc.identifier.urihttps://hdl.handle.net/20.500.12428/25283
dc.identifier.volume9
dc.identifier.wosWOS:000484457600061
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofBiomolecules
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectalpha-lipoic acid
dc.subjectbioavailability
dc.subjectformulations
dc.subjectclinical trial
dc.subjectdiabetic neuropathy
dc.subjectobesity
dc.subjectschizophrenia
dc.subjectsclerosis
dc.subjectpregnancy
dc.titleInsights on the Use of ?-Lipoic Acid for Therapeutic Purposes
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu